CJC-1295 research guide for Avelar. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
CJC-1295 isn't stocked on pharmacy shelves in Avelar or virtually any local market — it's a research compound supplied via a dedicated online market. This matters because CJC-1295 quality differs enormously across the market — from verified research-grade material to mislabeled or underdosed compounds — and the vendor is the entire quality system. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. This guide gives Avelar researchers the methodology to assess vendor quality rigorously and source research-grade CJC-1295 with confidence.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Avelar comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Assessing CJC-1295 vendors starts with the COA: locate the batch-specific certificate prior to buying, not after. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone cannot verify molecular identity. Strong quality indicators beyond COA quality: documented vendor history spanning multiple years, responsive technical support who understand testing methodology, and temperature-appropriate packaging with desiccant. For Avelar researchers making a first CJC-1295 purchase: work through this evaluation framework first, start with a modest quantity, and confirm the COA batch number matches your received product before use.
Order CJC-1295 — ships to Avelar
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human therapeutic use by the FDA or comparable health authorities — all information here is educational. Proper handling of CJC-1295 requires strict sterile technique during reconstitution — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and cold chain maintenance from receipt through use. The primary quality-related safety risk in CJC-1295 research is endotoxin from inadequately tested product — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. Protocol documentation — documenting product details, dates, and administration precisely — is a sound practice for any CJC-1295 protocol that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
